2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $195M | $246M | $271M | $325M | $401M |
Cost of Revenue | $38M | $43M | $51M | $53M | $63M |
Gross Profit | $157M | $204M | $220M | $272M | $339M |
Gross Profit % | 81% | 83% | 81% | 84% | 84% |
R&D Expenses | $54M | $66M | $81M | $84M | $98M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $5.8M | $71M | $121M | -$81M | -$283M |
Dep. & Amort. | $5.9M | $7.1M | $9.2M | $10M | $11M |
Def. Tax | -$2.8M | -$1.6M | -$2.4M | $5.1M | -$4M |
Stock Comp. | $7.3M | $6.5M | $14M | $19M | $0 |
Chg. in WC | $50M | $21M | -$2.8M | $39M | $37M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $129M | $146M | $88M | $190M | $192M |
ST Investments | $109M | $36M | $96M | $113M | $256M |
Cash & ST Inv. | $238M | $182M | $184M | $303M | $447M |
Receivables | $66M | $68M | $79M | $77M | $82M |
Inventory | $4.8M | $6.5M | $10M | $9.9M | $8.9M |
Cellebrite exceeded its 2024 revenue and adjusted EBITDA targets, achieving 25% ARR growth and generating $122 million in free cash flow.
The company aims to migrate 50% of its installed base to the Insights product suite by the end of 2025, up from 20% in 2024, while expanding Guardian and Pathfinder solutions, which saw strong ARR growth in 2024.
For 2025, Cellebrite projects ARR growth of 21%-25% ($480M-$495M) and revenue growth of 20%-22% ($480M-$490M), with adjusted EBITDA expected to range from $113M to $123M (24%-25% margin).
The company achieved FedRAMP Ready status at a high level, which is expected to double its TAM in the U.S. federal market, with significant growth anticipated in 2026.
Investments in AI and cloud-based solutions continue to drive adoption, with cloud ARR nearly doubling in 2024 and new Gen AI features introduced for Guardian to enhance investigative efficiency.